Welcome to our dedicated page for Healthwarehouse news (Ticker: HEWA), a resource for investors and traders seeking the latest updates and insights on Healthwarehouse stock.
HealthWarehouse.com is an OTCQB-traded healthcare e-commerce company that sells and delivers prescription and over-the-counter medications nationwide through a NABP Approved Digital Pharmacy platform. Company updates commonly cover financial results, prescription volume, direct-to-consumer activity, partner-services revenue, fulfillment capacity, and technology investments focused on patient experience, operational efficiency, and scalability.
Recurring news also addresses business partnerships for prescription and OTC fulfillment, product-catalog changes, cold-chain shipping capabilities, and shifts in categories such as compounded GLP-1 medications. Capital items, including convertible-note maturity changes, appear alongside operating updates for the digital pharmacy business.
HealthWarehouse.com (OTCQB: HEWA) reported first-quarter 2026 net sales of $6.3 million, down 57.8% year-over-year as FDA actions reduced compounded GLP-1 sales. Net loss was $361,000 versus prior-year net income of $178,000; Adjusted EBITDA was -$28,000, down from $561,000.
Gross margin improved to 52.1% and SG&A fell 15.5%. Over-the-counter sales rose 61.9%. The company highlighted technology investments and a new AI-focused partnership with healthwords.ai to support future growth and operational efficiency.
HealthWarehouse.com (OTCQB:HEWA) announced a strategic partnership with UK-based healthwords.ai on April 23, 2026. Per the agreement, healthwords.ai will acquire HealthWarehouse's direct-to-consumer assets, including its website and U.S. customer base, for an approximate aggregate value of $10.0 million.
Transaction consideration includes $3.5 million cash, a $3.6 million promissory note, and a 12.5% equity interest in healthwords.ai's parent. Closing is subject to healthwords.ai fulfilling the financial terms. Upon closing, HealthWarehouse will provide fulfillment and other services to healthwords.ai under a separate agreement.
NextPlat (NASDAQ: NXPL) announced a collaboration with HealthWarehouse to enable nationwide prescription and OTC fulfillment to all 50 U.S. states, expanding PharmcoRx beyond Florida.
The agreement leverages HealthWarehouse's NABP‑accredited digital pharmacy and national fulfillment to support rapid e-commerce expansion and revenue growth in 2026.
HealthWarehouse.com (OTCQB:HEWA) reported record 2025 results with $49.0 million in net sales, a 45.8% increase year-over-year, net income of $265,000, and Adjusted EBITDA $1.6 million. The company generated positive cash flow of $1.6 million and saw strong B2B partner-services growth.
Management warned that loss of authority to dispense certain high-dollar compounded GLP-1 medications will materially affect 2026 sales until replaced by new partners or expanded catalogs.
HealthWarehouse.com (OTCQB:HEWA) reported third-quarter 2025 results for the period ended September 30, 2025.
Total net sales were $8.4M for Q3 (down 6.8% year-over-year) and $39.1M year-to-date (up 96.6% year-over-year). The company posted a Q3 net loss of $72k and YTD net income of $334k. Adjusted EBITDA was $343k for Q3 and $1.4M for the nine months. Management attributed the Q3 sales slowdown to reduced DTC sales of compounded GLP-1s after FDA temporary approvals lapsed, while partner services drove YTD growth. Gross margin was 42.8% in Q3 and 34.0% YTD. SG&A increased year-to-date, reflecting higher pharmacy labor, legal, advertising and rent.
HealthWarehouse.com (OTCQB:HEWA) reported exceptional growth in Q2 2025, with net sales reaching $15.7 million, marking a 182% increase from Q2 2024. The company achieved net income of $228,000 and Adjusted EBITDA of $568,000 for the quarter.
The growth was primarily driven by a 495% increase in partner services revenues, though direct-to-consumer prescription business declined. Gross profit reached $5.2 million, but margins decreased to 32.9% due to lower margins in Partner Services. The company noted potential headwinds from the FDA's announcement regarding GLP1 drugs shortage ending, which may impact future results.
HealthWarehouse.com (OTCQB:HEWA) reported significant growth for the full year 2024, with net sales reaching $33.6 million, marking a 66% increase from 2023. The growth was primarily driven by a 78% increase in prescription revenues, reaching $30.9 million, though offset by a 6.3% decline in over-the-counter sales.
The company reported a net loss of $333,000 for the year, but achieved positive cash flow with Adjusted EBITDA of $1.1 million. The fourth quarter showed strong performance with net income of $189,000 and Adjusted EBITDA of $523,000.
While gross profit increased by 16% to $14.1 million, the gross margin percentage decreased from 60% to 42% due to lower margins in prescription sales. Operating expenses remained controlled, with SG&A expenses increasing only 3.1% despite the significant revenue growth.
HealthWarehouse.com (OTC:HEWA) reported record Q3 2024 results with net sales of $9.0 million, an 89% increase from Q3 2023. The company achieved net income of $74,000 and Adjusted EBITDA of $405,000. Prescription sales grew 96.3% to $8.3 million, driven by strong growth in GLP-1 weight loss medications. Gross profit increased to $3.8 million, though margins decreased to 42% due to price competition. The company also secured extension of convertible note maturity to 2026, strengthening its capital position.
HealthWarehouse.com (OTC:HEWA) reported Q2 2024 results with net sales of $5.8 million, a 9% increase from Q2 2023. The growth was driven by strong performance in partner services and B2C prescription revenue, particularly from GLP-1 weight loss medications. However, the company posted a net loss of $344,000 for Q2 and $596,000 for H1 2024. Prescription sales rose 12.8% to $5.1 million in Q2, while over-the-counter sales decreased 14.3% to $643,000. Gross profit declined due to lower margins, but operating expenses decreased by 10.1%. The company's Adjusted EBITDA broke even for Q2, improving from a $152,000 loss in Q2 2023.